207 related articles for article (PubMed ID: 23660577)
1. Zidovudine impairs immunological recovery on first-line antiretroviral therapy: collaborative analysis of cohort studies in southern Africa.
Wandeler G; Gsponer T; Mulenga L; Garone D; Wood R; Maskew M; Prozesky H; Hoffmann C; Ehmer J; Dickinson D; Davies MA; Egger M; Keiser O;
AIDS; 2013 Sep; 27(14):2225-32. PubMed ID: 23660577
[TBL] [Abstract][Full Text] [Related]
2. Anaemia and zidovudine-containing antiretroviral therapy in paediatric antiretroviral programmes in the IeDEA Paediatric West African Database to evaluate AIDS.
Renner LA; Dicko F; Kouéta F; Malateste K; Gueye RD; Aka E; Eboua TK; Azondékon A; Okomo U; Touré P; Ekouévi D; Leroy V;
J Int AIDS Soc; 2013 Sep; 16(1):18024. PubMed ID: 24047928
[TBL] [Abstract][Full Text] [Related]
3. Response to zidovudine/didanosine-containing combination antiretroviral therapy among HIV-1 subtype C-infected adults in Botswana: two-year outcomes from a randomized clinical trial.
Bussmann H; Wester CW; Thomas A; Novitsky V; Okezie R; Muzenda T; Gaolathe T; Ndwapi N; Mawoko N; Widenfelt E; Moyo S; Musonda R; Mine M; Makhema J; Moffat H; Essex M; Degruttola V; Marlink RG
J Acquir Immune Defic Syndr; 2009 May; 51(1):37-46. PubMed ID: 19282782
[TBL] [Abstract][Full Text] [Related]
4. Tenofovir or zidovudine in second-line antiretroviral therapy after stavudine failure in southern Africa.
Wandeler G; Gerber F; Rohr J; Chi BH; Orrell C; Chimbetete C; Prozesky H; Boulle A; Hoffmann CJ; Gsponer T; Fox MP; Zwahlen M; Egger M;
Antivir Ther; 2014; 19(5):521-5. PubMed ID: 24296645
[TBL] [Abstract][Full Text] [Related]
5. A comparison of two dosing regimens of zidovudine in Thai adults with early symptomatic HIV infection. Conducting clinical HIV trials in South-East Asia.
Phanuphak P; Grayson ML; Sirivichayakul S; Suwanagool S; Ruxrungtham K; Hanvanich M; Ratanasuwan W; Ubolyam S; Hughes MD; Wanke CA; Hammer SM
Aust N Z J Med; 2000 Feb; 30(1):11-20. PubMed ID: 10800872
[TBL] [Abstract][Full Text] [Related]
6. Early upper digestive tract side effects of zidovudine with tenofovir plus emtricitabine in West African adults with high CD4 counts.
Ouattara E; Danel C; Moh R; Gabillard D; Peytavin G; Konan R; Carrou JL; Bohoussou F; Eholie SP; Anglaret X
J Int AIDS Soc; 2013 Apr; 16(1):18059. PubMed ID: 23639243
[TBL] [Abstract][Full Text] [Related]
7. Triple nucleoside reverse transcriptase inhibitor- vs. nonnucleoside reverse transcriptase inhibitor-containing regimens as first-line therapy: efficacy and durability in a prospective cohort of French HIV-infected patients.
Cuzin L; Pugliese P; Bugnon F; Delpierre C; Cua E; Billaud E; Massip P; Raffi F; Dellamonica P
HIV Med; 2005 Nov; 6(6):388-95. PubMed ID: 16268820
[TBL] [Abstract][Full Text] [Related]
8. Tenofovir in second-line ART in Zambia and South Africa: collaborative analysis of cohort studies.
Wandeler G; Keiser O; Mulenga L; Hoffmann CJ; Wood R; Chaweza T; Brennan A; Prozesky H; Garone D; Giddy J; Chimbetete C; Boulle A; Egger M;
J Acquir Immune Defic Syndr; 2012 Sep; 61(1):41-8. PubMed ID: 22743595
[TBL] [Abstract][Full Text] [Related]
9. Monitoring and switching of first-line antiretroviral therapy in adult treatment cohorts in sub-Saharan Africa: collaborative analysis.
Haas AD; Keiser O; Balestre E; Brown S; Bissagnene E; Chimbetete C; Dabis F; Davies MA; Hoffmann CJ; Oyaro P; Parkes-Ratanshi R; Reynolds SJ; Sikazwe I; Wools-Kaloustian K; Zannou DM; Wandeler G; Egger M;
Lancet HIV; 2015 Jul; 2(7):e271-8. PubMed ID: 26423252
[TBL] [Abstract][Full Text] [Related]
10. High incidence of zidovudine induced anaemia in HIV infected patients in eastern India.
Agarwal D; Chakravarty J; Chaube L; Rai M; Agrawal NR; Sundar S
Indian J Med Res; 2010 Oct; 132():386-9. PubMed ID: 20966515
[TBL] [Abstract][Full Text] [Related]
11. A randomized factorial trial comparing 4 treatment regimens in treatment-naive HIV-infected persons with AIDS and/or a CD4 cell count <200 cells/μL in South Africa.
; Ratsela A; Polis M; Dhlomo S; Emery S; Grandits G; Khabo P; Khanyile T; Komati S; Neaton JD; Naidoo LC; Magongoa D; Qolohle D
J Infect Dis; 2010 Nov; 202(10):1529-37. PubMed ID: 20942650
[TBL] [Abstract][Full Text] [Related]
12. Long-term effectiveness and safety of didanosine combined with lamivudine and efavirenz or nevirapine in antiretroviral-naive patients: a 9-year cohort study in Senegal.
Laurent C; Tchatchueng Mbougua JB; Ngom Guèye NF; Etard JF; Diouf A; Landman R; Molinari N; Girard PM; Sow PS; Ndoye I; Delaporte E;
Trop Med Int Health; 2011 Feb; 16(2):217-22. PubMed ID: 21087377
[TBL] [Abstract][Full Text] [Related]
13. Anemia in people on second line antiretroviral treatment in Lilongwe, Malawi: a cross-sectional study.
Ngongondo M; Rosenberg NE; Stanley CC; Lim R; Ongubo D; Broadhurst R; Speight C; Flick R; Tembo P; Hosseinpour MC
BMC Infect Dis; 2018 Jan; 18(1):39. PubMed ID: 29334932
[TBL] [Abstract][Full Text] [Related]
14. A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naive individuals with HIV infection: selection of thymidine analog regimen therapy (START I).
Squires KE; Gulick R; Tebas P; Santana J; Mulanovich V; Clark R; Yangco B; Marlowe SI; Wright D; Cohen C; Cooley T; Mauney J; Uffelman K; Schoellkopf N; Grosso R; Stevens M
AIDS; 2000 Jul; 14(11):1591-600. PubMed ID: 10983646
[TBL] [Abstract][Full Text] [Related]
15. Different Degrees of Immune Recovery Using Antiretroviral Regimens with Vonavir or Zidovudine/Lamivudine/Efavirenz in HIVPositive Patients Receiving First Line Treatment in Iran.
Sadeghi L; Moallemi S; Tabatabai RA; Esmaeilzadeh A; Ahsani-Nasab S; Ahmadi NE; Bayanolhagh S; Lolaie M; Narouei A; SeyedAlinaghi S; Mohraz M
Infect Disord Drug Targets; 2018; 18(3):207-213. PubMed ID: 29308748
[TBL] [Abstract][Full Text] [Related]
16. Is zidovudine first-line therapy virologically comparable to tenofovir in resource-limited settings?
Labhardt ND; Bader J; Lejone TI; Ringera I; Puga D; Glass TR; Klimkait T
Trop Med Int Health; 2015 Jul; 20(7):914-8. PubMed ID: 25782332
[TBL] [Abstract][Full Text] [Related]
17. Outcomes of antiretroviral treatment in programmes with and without routine viral load monitoring in Southern Africa.
Keiser O; Chi BH; Gsponer T; Boulle A; Orrell C; Phiri S; Maxwell N; Maskew M; Prozesky H; Fox MP; Westfall A; Egger M;
AIDS; 2011 Sep; 25(14):1761-9. PubMed ID: 21681057
[TBL] [Abstract][Full Text] [Related]
18. Predictors of optimal viral suppression in patients switched to abacavir, lamivudine, and zidovudine: the Swiss HIV Cohort Study.
Wolbers M; Opravil M; von Wyl V; Hirschel B; Furrer H; Cavassini M; Vernazza P; Bernasconi E; Battegay M; Yerly S; Günthard H; Bucher HC;
AIDS; 2007 Oct; 21(16):2201-7. PubMed ID: 18090047
[TBL] [Abstract][Full Text] [Related]
19. Anemia among HIV Infected Individuals Taking ART with and without Zidovudine at Addis Ababa, Ethiopia.
Tamir Z; Alemu J; Tsegaye A
Ethiop J Health Sci; 2018 Jan; 28(1):73-82. PubMed ID: 29622909
[TBL] [Abstract][Full Text] [Related]
20. Treatment initiation with zidovudine-containing potent antiretroviral therapy impairs CD4 cell count recovery but not clinical efficacy.
Huttner AC; Kaufmann GR; Battegay M; Weber R; Opravil M
AIDS; 2007 May; 21(8):939-46. PubMed ID: 17457087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]